Linked Data API

Show Search Form

Search Results

100706
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Influenza: Vaccination more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what assessment he has made of the (a) uptake and (b) effectiveness of the influenza immunisation vaccine campaign. more like this
star this property tabling member constituency Belfast North more like this
star this property tabling member printed
Mr Nigel Dodds more like this
star this property uin 211669 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer remove filter
unstar this property answer text <p>Immunisation against influenza for the 2014-15 season commenced in September and good progress has been made. Provisional percentage vaccine uptake rates for various groups as at week ending 19 October are shown in the following table (figures relate to England):</p><p> </p><p> </p><p> </p><table><tbody><tr><td><p>Age Group</p></td><td><p>Uptake Rate (%)</p></td></tr><tr><td><p>People aged 65 years or older</p></td><td><p>44.6</p></td></tr><tr><td><p>People aged six months to under 65 years in risk groups</p></td><td><p>25.2</p></td></tr><tr><td><p>Pregnant women</p></td><td><p>22.4</p></td></tr><tr><td><p>Children aged two years old</p></td><td><p>8.1</p></td></tr><tr><td><p>Children aged three years old</p></td><td><p>8.8</p></td></tr><tr><td><p>Children aged four years old</p></td><td><p>6.5</p></td></tr></tbody></table><p> </p><p> </p><p> </p><p>Vaccine uptake rates for those aged 65 and over, those under 65 with a clinical condition, and pregnant women are slightly higher than at the same point in the last two years. Uptake for two and three year olds is lower than at this point a year ago. For the new cohort of four year olds, vaccination levels are similar to those for two and three year olds.</p><p> </p><p> </p><p> </p><p>It is not possible to make an assessment of the effectiveness of the 2014-15 influenza immunisation programme at this very early stage before the influenza virus is circulating. The planned programme of campaign communication is ongoing.</p><p> </p><p> </p><p> </p><p> </p><p> </p>
star this property answering member constituency Battersea more like this
star this property answering member printed Jane Ellison more like this
star this property question first answered
less than 2014-10-30T16:57:25.8382413Zmore like thismore than 2014-10-30T16:57:25.8382413Z
star this property answering member
3918
star this property label Biography information for Jane Ellison more like this
star this property tabling member
1388
unstar this property label Biography information for Lord Dodds of Duncairn more like this
100707
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Neural Tube Defects: Folic Acid more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, what steps his Department is taking to raise awareness of the use of folic acid prior to conception as a preventative measure for neural tube defects. more like this
star this property tabling member constituency Belfast North more like this
star this property tabling member printed
Mr Nigel Dodds more like this
star this property uin 211670 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer remove filter
unstar this property answer text <p>Public Health England (PHE) strongly encourages women to take a folic acid supplement from before they are pregnant to the 12th week of pregnancy, to reduce the risk of having a baby with a neural tube defect. This advice is included in public health messages around pregnancy and planning a pregnancy.</p><p> </p><p> </p><p> </p><p>National Institute for Health and Care Excellence guidance states that advice on folic acid supplementation should be provided as part of antenatal care at first contact with a healthcare professional. Advice on folic acid supplementation for women who are pregnant or planning a pregnancy, is disseminated through a variety of sources including the NHS Choices website, the NHS Information Service for Parents, the charity ‘Tommy’s’, and Start4Life - PHE’s campaign to give babies the best start in life and reduce the risk of poor health in the future.</p><p> </p><p> </p><p> </p><p>PHE has recently established a media partnership to communicate the key healthy behaviour messages prior to conception in more mainstream women’s magazine media.</p><p> </p><p><strong> </strong></p><p> </p><p>In addition, the Department has commissioned the Behavioural Insights Team to look at innovative approaches to raising awareness of the need to take folic acid supplements during pregnancy. This programme of work is scheduled for completion by the end of January 2015.</p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p>
star this property answering member constituency Battersea more like this
star this property answering member printed Jane Ellison more like this
star this property question first answered
less than 2014-10-30T16:59:32.35103Zmore like thismore than 2014-10-30T16:59:32.35103Z
star this property answering member
3918
star this property label Biography information for Jane Ellison more like this
star this property tabling member
1388
unstar this property label Biography information for Lord Dodds of Duncairn more like this
100713
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Abortion: Republic of Ireland more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how many Irish nationals had (a) one and (b) more than one abortion via NHS England in 2013. more like this
star this property tabling member constituency The Wrekin more like this
star this property tabling member printed
Mark Pritchard more like this
star this property uin 211676 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer remove filter
unstar this property answer text <p>No Irish nationals have had one or more than one abortion via NHS England in 2013.</p><p> </p> more like this
star this property answering member constituency Battersea more like this
star this property answering member printed Jane Ellison more like this
star this property question first answered
less than 2014-10-30T17:15:07.8107781Zmore like thismore than 2014-10-30T17:15:07.8107781Z
star this property answering member
3918
star this property label Biography information for Jane Ellison more like this
star this property tabling member
1576
unstar this property label Biography information for Mark Pritchard more like this
100716
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Assistive Technology: Annual Reports more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, if he will publish the Risk Assessment for his Department's decision to bring the production of the annual report on Research and Development Work Relating to Assistive Technology in house from 2015. more like this
star this property tabling member constituency Denton and Reddish more like this
star this property tabling member printed
Andrew Gwynne more like this
star this property uin 211709 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer remove filter
unstar this property answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
211707 more like this
211708 more like this
211710 more like this
star this property question first answered
less than 2014-10-30T16:13:24.0967252Zmore like thismore than 2014-10-30T16:13:24.0967252Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
1506
unstar this property label Biography information for Andrew Gwynne more like this
100717
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Assistive Technology: Annual Reports more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, if he will publish the Impact Assessment for his Department's decision to bring the production of the annual report on Research and Development Work Relating to Assistive Technology in house from 2015. more like this
star this property tabling member constituency Denton and Reddish more like this
star this property tabling member printed
Andrew Gwynne more like this
star this property uin 211710 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer remove filter
unstar this property answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
211707 more like this
211708 more like this
211709 more like this
star this property question first answered
less than 2014-10-30T16:13:24.2061433Zmore like thismore than 2014-10-30T16:13:24.2061433Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
1506
unstar this property label Biography information for Andrew Gwynne more like this
100718
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Assistive Technology: Annual Reports more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, when he plans to publish the next annual report on Research and Development Work Relating to Assistive Technology. more like this
star this property tabling member constituency Denton and Reddish more like this
star this property tabling member printed
Andrew Gwynne more like this
star this property uin 211707 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer remove filter
unstar this property answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
211708 more like this
211709 more like this
211710 more like this
star this property question first answered
less than 2014-10-30T16:13:23.9161629Zmore like thismore than 2014-10-30T16:13:23.9161629Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
1506
unstar this property label Biography information for Andrew Gwynne more like this
100719
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Assistive Technology: Annual Reports more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, when he expects the next annual report on Research and Development Work Relating to Assistive Technology to be laid before parliament. more like this
star this property tabling member constituency Denton and Reddish more like this
star this property tabling member printed
Andrew Gwynne more like this
star this property uin 211708 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer remove filter
unstar this property answer text <p>Section 22 of the Chronically Sick and Disabled Persons Act 1970 sets out the following requirement:</p><p> </p><p> </p><p> </p><p>“The Secretary of State shall as respects each year lay before Parliament a report on the progress made during that year in research and development work carried out by or on behalf of any Minister of the Crown in relation to equipment that might increase the range of activities and independence or well-being of disabled persons, and in particular such equipment that might improve the indoor and outdoor mobility of such persons.”</p><p> </p><p> </p><p> </p><p>In recent years the report has been produced by the Foundation for Assistive Technology and this contract expired in June 2014 following production of the report for 2013-14. Future reports will be produced by the Department and it is expected that the report for 2014-15 will be laid before Parliament and published in July 2015.</p><p> </p><p>There has been no specific impact or risk assessment. The Government will continue to meet the requirement set out in section 22.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property grouped question UIN
211707 more like this
211709 more like this
211710 more like this
star this property question first answered
less than 2014-10-30T16:13:24.0029324Zmore like thismore than 2014-10-30T16:13:24.0029324Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
1506
unstar this property label Biography information for Andrew Gwynne more like this
100720
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Osteoporosis: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how much has been spent on prescriptions for the treatment of osteoporosis in each of the last five years. more like this
star this property tabling member constituency Leicester West more like this
star this property tabling member printed
Liz Kendall more like this
star this property uin 211731 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer remove filter
unstar this property answer text <p>Information on National Health Service expenditure on drugs for the treatment of osteoporosis in primary and secondary care is in the table.</p><p> </p><p> </p><p> </p><p>Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections:</p><p> </p><p>6.6 Drugs affecting bone metabolism</p><p> </p><p>9.5.1.1 Calcium supplements</p><p> </p><p>9.6 Vitamins (colecalciferol and ergocalciferol only)</p><p> </p><p><strong> </strong></p><p> </p><table><tbody><tr><td colspan="11"><p>Cost of drugs for the treatment of osteoporosis, England<sup>1</sup></p></td></tr><tr><td><p>Drug Name<sup>2</sup></p></td><td colspan="5"><p>Primary Care</p><p>(£ million)</p></td><td colspan="5"><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>Year</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td><td><p>2009</p></td><td><p>2010</p></td><td><p>2011</p></td><td><p>2012</p></td><td><p>2013</p></td></tr><tr><td><p>Alendronic Acid</p></td><td><p>14.0</p></td><td><p>12.4</p></td><td><p>10.8</p></td><td><p>9.7</p></td><td><p>8.9</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.4</p></td></tr><tr><td><p>Alendronic Acid and Colecalciferol</p></td><td><p>1.4</p></td><td><p>1.2</p></td><td><p>0.9</p></td><td><p>0.7</p></td><td><p>0.6</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Calcitonin (Salmon)</p></td><td><p>0.3</p></td><td><p>0.3</p></td><td><p>0.2</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Calcium</p></td><td><p>4.2</p></td><td><p>4.7</p></td><td><p>4.5</p></td><td><p>3.7</p></td><td><p>3.3</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td><td><p>0.9</p></td></tr><tr><td><p>Calcium and Colecalciferol</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.2</p></td><td><p>2.2</p></td><td><p>2.1</p></td><td><p>2.2</p></td><td><p>2.3</p></td></tr><tr><td><p>Clodronic Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>2.9</p></td><td><p>2.4</p></td><td><p>1.6</p></td><td><p>1.2</p></td><td><p>0.9</p></td></tr><tr><td><p>Colecalciferol</p></td><td><p>42.4</p></td><td><p>48.3</p></td><td><p>58.5</p></td><td><p>67.6</p></td><td><p>75.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.4</p></td><td><p>1.2</p></td></tr><tr><td><p>Denosumab</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.8</p></td><td><p>1.9</p></td><td><p>0.0</p></td><td><p>0.1</p></td><td><p>0.9</p></td><td><p>2.3</p></td><td><p>9.9</p></td></tr><tr><td><p>Disodium Etidronate</p></td><td><p>1.3</p></td><td><p>1.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Ergocalciferol</p></td><td><p>4.3</p></td><td><p>7.8</p></td><td><p>8.0</p></td><td><p>7.0</p></td><td><p>6.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.2</p></td><td><p>0.3</p></td></tr><tr><td><p>Ibandronic Acid</p></td><td><p>12.1</p></td><td><p>12.1</p></td><td><p>11.4</p></td><td><p>10.6</p></td><td><p>4.7</p></td><td><p>2.1</p></td><td><p>2.0</p></td><td><p>1.8</p></td><td><p>1.5</p></td><td><p>0.9</p></td></tr><tr><td><p>Pamidronic Acid</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>9.6</p></td><td><p>9.1</p></td><td><p>9.4</p></td><td><p>9.4</p></td><td><p>8.7</p></td></tr><tr><td><p>Risedronate Sodium and Risedronate Acid</p></td><td><p>27.9</p></td><td><p>22.9</p></td><td><p>11.6</p></td><td><p>2.4</p></td><td><p>2.0</p></td><td><p>0.8</p></td><td><p>0.6</p></td><td><p>0.3</p></td><td><p>0.1</p></td><td><p>0.1</p></td></tr><tr><td><p>Sodium Clodronate</p></td><td><p>7.8</p></td><td><p>7.2</p></td><td><p>6.3</p></td><td><p>5.5</p></td><td><p>4.3</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Strontium Ranelate</p></td><td><p>7.0</p></td><td><p>7.8</p></td><td><p>9.0</p></td><td><p>9.2</p></td><td><p>7.3</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.2</p></td></tr><tr><td><p>Teriparatide</p></td><td><p>0.3</p></td><td><p>0.4</p></td><td><p>0.4</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>2.7</p></td><td><p>2.8</p></td><td><p>2.7</p></td><td><p>3.1</p></td><td><p>3.2</p></td></tr><tr><td><p>Zoledronic Acid</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>16.7</p></td><td><p>18.0</p></td><td><p>20.9</p></td><td><p>23.7</p></td><td><p>25.7</p></td></tr><tr><td><p>Other Calcium Supplement Preps</p></td><td><p>0.5</p></td><td><p>0.6</p></td><td><p>0.6</p></td><td><p>0.5</p></td><td><p>0.5</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.0</p></td></tr><tr><td><p>Other drugs<sup>3</sup></p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td><td><p>0.0</p></td><td><p>0.2</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.1</p></td><td><p>0.0</p></td></tr><tr><td><p>TOTAL</p></td><td><p>123.8</p></td><td><p>126.8</p></td><td><p>123.4</p></td><td><p>119.1</p></td><td><p>115.4</p></td><td><p>39.6</p></td><td><p>39.6</p></td><td><p>42.3</p></td><td><p>46.2</p></td><td><p>55.0</p></td></tr></tbody></table><p> </p><p><sup>1 </sup>Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.</p><p> </p><p><sup>2</sup> The patent for some of these drugs may have expired during this period.</p><p> </p><p><sup>3</sup> “Other drugs” includes Calcium and Colecalciferol and Ergocalciferol, Calcium and Etidronic Acid, Calcium and Risedronic and Colecalciferol, Disodium Pamidronate, Ergocalciferol and Calcium, Etidronic Acid, Hydroxyapatite, Parathyroid Hormone, Salcatonin, Tiludronic Acid, other Bisphosphonate and other Preparations.</p><p> </p><p> </p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for osteoporosis.</p><p> </p><p> </p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2014-10-30T16:09:20.4432894Zmore like thismore than 2014-10-30T16:09:20.4432894Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4026
unstar this property label Biography information for Liz Kendall more like this
100722
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Neurology: Nurses more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how many full-time equivalent specialist nurses for a neurological condition were employed in each region of England in each of the last five years. more like this
star this property tabling member constituency Leicester West more like this
star this property tabling member printed
Liz Kendall more like this
star this property uin 211733 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer remove filter
unstar this property answer text <p>The National Health Service annual workforce census provides information on the number of nursing, midwifery and health visiting staff employed in the NHS in England but does not separately identify specialist nurses employed in neurological conditions.</p><p> </p><p> </p><p> </p><p>It is for local NHS organisations with their knowledge of the healthcare needs of their local population to invest in training for specialist skills and to deploy specialist nurses. Specialist nurses provide invaluable support for patients and their families. They are able to provide specialist treatment and advice and act as a gateway to other members of the multidisciplinary team, which can both save the NHS money and, more importantly, improve care and outcomes for patients.</p><p> </p><p> </p><p> </p><p>Health Education England (HEE) supports employers with Continuous Personal and Professional Development. HEE's planning process has created the opportunity for employers, through their membership of local education training boards, to prioritise investment between training the future supply of healthcare professional and the development of existing staff, but it is currently for these local partnerships to identify their relative priorities for investment.</p><p> </p><p> </p><p> </p>
star this property answering member constituency Central Suffolk and North Ipswich more like this
star this property answering member printed Dr Daniel Poulter more like this
star this property question first answered
less than 2014-10-30T16:25:48.4053292Zmore like thismore than 2014-10-30T16:25:48.4053292Z
star this property answering member
3932
star this property label Biography information for Dr Dan Poulter more like this
star this property tabling member
4026
unstar this property label Biography information for Liz Kendall more like this
100724
star this property registered interest false more like this
star this property date less than 2014-10-23more like thismore than 2014-10-23
star this property answering body
Department of Health more like this
star this property answering dept id 17 remove filter
star this property answering dept short name Health more like this
star this property answering dept sort name Health more like this
star this property hansard heading Motor Neurone Disease: Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health, how much has been spent on the prescription of drugs for the treatment of motor neurone disease in each of the last five years. more like this
star this property tabling member constituency Leicester West more like this
star this property tabling member printed
Liz Kendall more like this
star this property uin 211727 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer remove filter
unstar this property answer text <p>Information on National Health Service expenditure on drugs for the treatment of motor neurone disease in primary and secondary care is in the table.</p><p> </p><p><strong> </strong></p><p> </p><p>Riluzole is the only drug defined in the British National Formulary as being used for the treatment of motor neurone disease</p><p> </p><p> </p><p> </p><table><tbody><tr><td colspan="3"><p>Cost of riluzole, England<sup>1</sup></p></td></tr><tr><td><p>Year</p></td><td><p>Primary Care</p><p>(£ million)</p></td><td><p>Secondary Care</p><p>(£ million)</p></td></tr><tr><td><p>2009</p></td><td><p>3.8</p></td><td><p>1.2</p></td></tr><tr><td><p>2010</p></td><td><p>4.9</p></td><td><p>1.4</p></td></tr><tr><td><p>2011</p></td><td><p>5.5</p></td><td><p>1.4</p></td></tr><tr><td><p>2012</p></td><td><p>5.8</p></td><td><p>1.5</p></td></tr><tr><td><p>2013<sup>2</sup></p></td><td><p>2.3</p></td><td><p>1.0</p></td></tr></tbody></table><p> </p><p><sup>1</sup> Cost of drugs at NHS list price. It does not take account of discounts, dispensing costs, fees or prescription charges income.</p><p> </p><p><sup>2 </sup>The patent for riluzole expired in the first quarter of 2013.</p><p> </p><p><em>Source: </em></p><p> </p><p>Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care)</p><p> </p><p>Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care)</p><p> </p><p> </p><p> </p><p>Since a drug could be prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which it may have been prescribed. The information provided may therefore include costs from the prescribing of the drug for conditions other than for motor neurone disease.</p><p> </p>
star this property answering member constituency Mid Norfolk more like this
star this property answering member printed George Freeman more like this
star this property question first answered
less than 2014-10-30T16:04:31.3067599Zmore like thismore than 2014-10-30T16:04:31.3067599Z
star this property answering member
4020
star this property label Biography information for George Freeman more like this
star this property tabling member
4026
unstar this property label Biography information for Liz Kendall more like this